Name

Regrow Biosciences

Legal name

Regrow Biosciences Pvt Ltd

Website

https://regrow.in

Company type

Private

Founded year

1989

Operating status

Operating

Headcount range

251–500 employees

Ownership category

akta.pro rank

Product category

Regenerative Medicine / Cell Therapy

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Blood and Organ Banks (621991)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Cell Therapy Developers (Autologous) (HLAAABAA)

akta.pro secondary industries

Stem Cell–Based Regenerative Therapies (HLAAAGAA), Cartilage, Bone & Musculoskeletal Regeneration (HLAAAGAH), Cell & Tissue Banking (biobanking, cord blood/tissue) (HLAAAGAE), Cell Therapy Manufacturing Services (GMP, autologous/allogeneic) (HLAAAKAC)

Keywords

• Cell therapy products
• Regenerative medicine
• Stem cell banking
• Autologous biologics
• Orthopedic cell therapy

Headquarters

HQ city

Mumbai

HQ country

India

HQ region

Asia

Offices4 records

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Cell Therapy Products (OSSGROW, CARTIGROW, XTIKTR): Revenue from sale of patient-specific autologous cell therapy products. Each treatment is a one-time therapy where the patient's own cells are harvested, cultured, and reimplanted. Government purchases can be made through GeM (government e-marketplace). Products are covered by private and government insurance schemes. The company also offers franchise partnership for Biocell cord blood banking.
2. Cord Blood Stem Cell Banking (Biocell): Premium umbilical cord blood banking service offered across 600 Indian cities. Revenue generated from cord blood banking subscription/preservation fees. Service includes the privilege to access cell therapy products including OSSGROW and CARTIGROW for hip and knee repair (REGROW health cover).

Pricing tiers

Go-to-market motion2 records

Distribution channels5 records

Marketing channels6 records

Core offering

Regrow Biosciences manufactures patient-specific autologous cell therapy products—OSSGROW® (bone cell therapy for Avascular Necrosis), CARTIGROW® (cartilage cell therapy), and XTIKTR™ (epithelial cell therapy for urethral stricture)—produced by culturing the patient's own cells at a GMP facility in Lonavala, India. The company also operates BIOCELL®, a premium umbilical cord blood stem cell banking subscription service spanning 600+ Indian cities with attached future access to its cell therapy portfolio via REGROW health cover.

Product overview

Regrow Biosciences is a biotech company pioneering regenerative medicine through cell and stem cell-based products. The portfolio consists of four main offerings: OSSGROW® (world's first bone cell therapy for AVN with US FDA Orphan Drug Designation), CARTIGROW® (India's first cartilage cell therapy), XTIKTR™ (epithelial cell therapy for urethral stricture), and BIOCELL® (umbilical cord blood stem cell banking service). These products are underpinned by a proprietary three-pronged platform technology combining biological agents, biomechanical carriers, and delivery systems for targeted tissue repair. The company operates a GMP-compliant manufacturing facility at Lonavala, India, and maintains partnerships with over 340 doctors across 46 cities, having served more than 1,500 patients.

Differentiator

Problem solved

Functional benefit

Brands

• OSSGROW®: Patient-specific biological bone cell therapy for treatment of Avascular Necrosis (AVN). World's first bone cell therapy product.
• CARTIGROW®
• XTIKTR™
• BIOCELL®

Products and services

• OSSGROW® OSSGROW® is a patient-specific, biological regenerative bone cell therapy that uses autologous adult live cultured osteoblasts derived from the patient's own bone marrow to treat Avascular Necrosis (AVN). The therapy involves extracting 4ml of bone marrow, culturing osteoblast cells for 14-21 days, and implanting 48 million cultured cells into the damaged femoral head to initiate new blood supply, remove dead bone, and form new bone tissue.
• CARTIGROW® CARTIGROW® is a patient-specific, biological regenerative cartilage cell therapy that uses autologous chondrocyte implantation (ACI) to treat cartilage damage. The process involves arthroscopic extraction of healthy cartilage tissue, isolation and culture of chondrocyte cells for 2-3 weeks, and reimplantation of 48 million cultured chondrocytes onto the damaged joint area to regenerate hyaline cartilage.
• XTIKTR™ XTIKTR™ is a patient-specific, biological regenerative epithelial cell therapy that uses the patient's own cells to treat urethral stricture. Once epithelial cells are implanted, an epithelialization layer of new tissue is regenerated at the stricture site, relieving patient symptoms and restoring normal urine flow and sexual function.
• BIOCELL® Cord Blood Banking BIOCELL® is India's leading premium umbilical cord blood stem cell banking service offering therapeutic solutions to treat more than 100 approved medical conditions. The service is available across 600 Indian cities and serves over 50,000 parents. It includes the Sibling Program for cord blood transplantation and bundled REGROW health cover providing access to OSSGROW and CARTIGROW therapies for hip and knee repair.

Quantifiable outcome

• Over 1,000 patients have benefited through OSSGROW and CARTIGROW treatments
• +5 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles5 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Two partnerships are on record, tiered core and minor.

• Department of Biotechnology (DBT), Ministry of Science and Technology, Government of IndiacoreStrategic or Co-development PartnerRegrow collaborated with DBT for the development of XTIKTR, the urology-based cell therapy product. XTIKTR was developed with DBT support and launched commercially in 2020. This collaboration with a government scientific body demonstrates regulatory credibility and co-development of novel cell therapy.
• Third-Party Payment ProcessorsminorOthersThird-party payment processors handle payment collection for Regrow's services, adhering to PCI-DSS standards. Regrow does not store payment card details directly.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

Emerging players

• Athersys: Athersys is developing MultiStem®, an off-the-shelf cell therapy platform for indications including stroke and ARDS. Comparable as a regenerative medicine competitor advancing a cell therapy platform into multi-indication clinical development.

Regional players

• Reliance Life Sciences: Reliance Life Sciences operates an India-based stem cell and regenerative medicine business including cord blood banking (Reliance Cord Blood Bank) and cell therapy R&D — directly comparable to Regrow's Biocell cord blood banking and cell therapy portfolio within the same geography and customer base.
• Pharmicell: Pharmicell (Korea) develops and commercializes stem cell-based products including heart cell and cartilage therapies. Comparable as a regional autologous/cell therapy specialist with similar indications and commercial-stage maturity outside Regrow's home market.

Broad incumbents

• TiGenix (Takeda): TiGenix pioneered the first EMA-approved autologous chondrocyte cell therapy (ChondroCelect) before being acquired by Takeda. It is the most established global benchmark for cartilage cell therapy commercialization and now competes from within a large-incumbent pharma portfolio.
• Mesoblast: Mesoblast develops allogeneic cell-based medicines across inflammatory and cardiovascular indications. It is a broadly comparable regenerative medicine incumbent with FDA pathway experience that contrasts with Regrow's autologous approach.

Direct peers

• Stempeutics Research: Bangalore-based Stempeutics develops stem cell-based therapies (Stempeucel®) targeting critical limb ischemia and other indications with DCGI-aligned regulatory pathways — a domestic India peer operating in the same autologous/allogeneic cell therapy category.
• LifeCell International: LifeCell is one of India's largest private cord blood and stem cell banking operators serving expectant parents — a head-to-head Biocell® competitor on the consumer banking side of Regrow's business model.
• Vericel Corporation: Vericel develops and commercializes autologous cell therapies, most notably MACI (autologous cultured chondrocytes on a porcine collagen membrane) for cartilage repair — directly comparable to Regrow's CARTIGROW® ACI platform in product modality, indication, and target surgical customers.
• Cryoviva (Cryobank India): Cryoviva operates pan-India umbilical cord blood and stem cell banking services to expectant parents — a direct Biocell® competitor in pricing, distribution, and geography.
• Japan Tissue Engineering (J-TEC, FUJIFILM): J-TEC commercializes autologous cell therapies including cultured epidermal autografts (JACE) and autologous cartilage (JACC) — directly comparable business model to Regrow's curated autologous orthopedic and epithelial cell therapy products.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/RegrowIndia
• YouTubeyoutube.com/channel/UCdqQDB-OCJ5Dp3LbF226G9A/videos
• Facebookfacebook.com/regrow
• LinkedInlinkedin.com/company/regrowindia

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Regrow Biosciences